- Home
- PCVX vs HALO Comparison
PCVX vs HALO Comparison
Compare PCVX & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PCVX | HALO |
|---|---|---|
| Founded | 2013 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6B | 8.8B |
| IPO Year | 2020 | 2001 |
Fundamental Metrics
Financial Performance| Metric | PCVX | HALO |
|---|---|---|
| Price | $56.59 | $65.39 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 11 |
| Target Price | ★ $88.25 | $78.64 |
| AVG Volume (30 Days) | 963.3K | ★ 1.2M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 2.56 |
| Revenue | N/A | ★ $151,862,000.00 |
| Revenue This Year | N/A | $28.24 |
| Revenue Next Year | N/A | $12.56 |
| P/E Ratio | ★ N/A | $25.24 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.09 | $47.50 |
| 52 Week High | $65.00 | $82.22 |
Technical Indicators
Market Signals| Indicator | PCVX | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 37.35 | 49.62 |
| Support Level | $52.04 | $63.85 |
| Resistance Level | $56.04 | $68.00 |
| Average True Range (ATR) | 2.25 | 1.94 |
| MACD | -0.66 | -0.18 |
| Stochastic Oscillator | 0.00 | 40.68 |
Price Performance
Historical ComparisonAbout PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.